NEW IMMUNOGLOBULIN FOR TREATMENT OF ANTHRAX


Cite item

Full Text

Abstract

Aim. To experimentally assess activity and safety of anti-anthrax intravenous immunoglobulin manufactured on standard technology. Materials and methods. Plasma from selected donors vaccinated with combined anthrax vaccine was tested by enzyme immunoassay. Samples of plasma with increased titer of anti-anthrax antibodies were merged in one manufacturing load and fractionated in ethanol at negative temperature according to standard technology. Formulation of intravenous immunoglobulin was manufactured according to standard technology of acid-enzyme hydrolysis. Results. Proved medical technology of donors’ immune plasma fractionation provided 4 - 8-fold concentration of anti-anthrax antibodies. The finished product contained 5% of protein and was apyrogenic, non-toxic, thermostable, electrophoretically homogenous, had pH 6.65 and meet the requirements for manufacturing batches of human intravenous immunoglobulin. Conclusion. Protective effects of experimental human anti-anthrax immunoglobulin were comparable with control biological - equine anti-anthrax immunoglobulin for intramuscular use.

About the authors

D. V Borovsky

48 Central Research Institute of Ministry of Defense; Research Institute of Hematology and Blood Tranfusion, Kirov, Russia

A. N Shevtsov

48 Central Research Institute of Ministry of Defense; Research Institute of Hematology and Blood Tranfusion, Kirov, Russia

I. V Darmov

48 Central Research Institute of Ministry of Defense; Research Institute of Hematology and Blood Tranfusion, Kirov, Russia

M. Yu Lub

48 Central Research Institute of Ministry of Defense; Research Institute of Hematology and Blood Tranfusion, Kirov, Russia

G. A Zaytseva

48 Central Research Institute of Ministry of Defense; Research Institute of Hematology and Blood Tranfusion, Kirov, Russia

A. V Drobkova

48 Central Research Institute of Ministry of Defense; Research Institute of Hematology and Blood Tranfusion, Kirov, Russia

V. Yu Dolmatov

48 Central Research Institute of Ministry of Defense; Research Institute of Hematology and Blood Tranfusion, Kirov, Russia

References

  1. Бургасов П.Н., Рожков Г.И., Тамарин А.Л. и др. Метод оценки иммунитета по превентив- ным свойствам сыворотки крови и новая схема иммунизации людей против сибирской язвы. Имформ. бюлл. НИИМ МО РФ. 1965, 73: 33.
  2. Лобзин Ю.В., Волжанин В.М., Захарченко С.М. Сибирская язва. Клин. микробиол. антимикроб. химиотерап. 2002, 2: 104 - 127.
  3. Методы контроля медицинских иммунобиологических препаратов вводимых людям. Метод. ук. МУК 4.1/4.2.588-96. М., 1998.
  4. Наставление по применению ботулинических сывороток типов B, C, E, F, очищенных методом пептического переваривания, концентрированных. Утв. МЗ СССР 09.12.1983.
  5. Шарыгин С.Л. Препараты внутривенных им- муноглобулинов донорской плазмы для терапии бактериальных и вирусных инфекций (получение и клиническое применение). Дис. д-ра мед. наук. Киров, 1997.
  6. Шкуратова О.В. Разработка научно-методи- ческих основ технологии производства специфического препарата для лечения больных дифтерией. Автореф. дис. канд. биол. наук. Томск, 2002.
  7. Arnon S.S., Schechter R., Maslanka S.E. et al. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 2006, 354: 462 - 471.
  8. Cohn E. Blood proteins and their theraupevtic value. Science. 1945, 101: 51 - 56.
  9. Cohn E., Strong L., Hughes W. Preparations and properties of serum and plasma proteins. J. Amer. Chem. Soc. 1946, 68: 459.
  10. Hanna P. Lethal toxin actions and their consequences. J. Appl. Microbiology. 1999, 87: 285 - 287.
  11. Dixon T.C., Meselson M., Guillemin J. et al. Anthrax. N. Engl. J. Med. 1999, 341: 815 - 826.
  12. Spencer R.C. Bacillus anthracis. J. Clin. Pathol. 2003, 56: 182 - 187.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Borovsky D.V., Shevtsov A.N., Darmov I.V., Lub M.Y., Zaytseva G.A., Drobkova A.V., Dolmatov V.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies